Presenting Better Treatments through Bioavailability Enhancement, Macromolecule Delivery and Optimized Tabletting
SOMERSET, NJ , January 18, 2013 – Two scientists from Catalent Pharma Solutions, the global leader in oral drug delivery technology, are to present at ExL Pharma’s 2 nd Enhancing Drug Bioavailability and Solubility conference in Boston, MA. The conference will focus on emerging drug bioavailability and solubility enhancement strategies to maximize exposure and reduce the time-to-market of future drug products.
On Wednesday, January 23, 2013, Stephen Abele, Principal Formulation Scientist, Catalent Pharma Solutions, will be joined by Tapan Parikh, MS, PhD Candidate, St. John’s University, to present “New Modified-Release Technology & the Role of Physico-Chemical Properties of Polymers in Hot Melt Extrusion.”
Mr. Abele and Mr. Parikh’s presentation will explore the advantages of Catalent’s OptiDose™, hot melt extrusion technology that offers solid dispersion in polymeric carriers to enhance dissolution rates and bioavailability, ultimately leading to better treatments. They will compare the advantages of OptiDose over traditional bi-layer, tri-layer, loosely compressed, tablet-in-tablet and any other modified-release dosage forms.
Later that same day, Irena McGuffy, Manager of Softgel Formulation for Catalent, will present “Novel Softgel Delivery Systems for Bioavailability Enhancement, Macromolecule Delivery and Life-cycle Management”.
Ms. McGuffy’s presentation with examine new applications in Softgel technology for Lipid Based Drug Delivery Systems and consider: the expanded range of excipients for solubility and bioavailability enhancement applicable to Catalent’s OptiShell™ capsules; bioavailability enhancement of orally delivered macromolecules utilizing lipid-based delivery systems, permeation enhancers and targeted delivery; achieving targeted, delayed or extended release from softgel capsules using film coating systems and; softgel film coating for the purpose of development of fixed dose combinations or unique drug release profiles.
Catalent has more than 75 years’ experience and a wide range of innovative drug delivery solutions to improve product performance. The talent and expertise of more than 1,000 development and formulation scientists has helped solve some of the most complex bioavailability challenges and deliver effective treatments.
Visit www.catalent.com to learn more about Catalent’s modified release technologies.
ExL Pharma’s 2 nd Enhancing Drug Bioavailability and Solubility Conference will take place on January, 22 – 23, 2013 at the Omni Parker House Hotel in Boston, MA. A pre-conference workshop will take place on Monday January 21, 2013. For more information on the workshop or conference see http://www.exlpharma.com/bioavailability
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com .